当前位置: 首页 >> 检索结果
1358. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
作者: Ken Kato.;Ryunosuke Machida.;Yoshinori Ito.;Hiroyuki Daiko.;Soji Ozawa.;Takashi Ogata.;Hiroki Hara.;Takashi Kojima.;Tetsuya Abe.;Takeo Bamba.;Masaya Watanabe.;Hirofumi Kawakubo.;Yuichi Shibuya.;Yasuhiro Tsubosa.;Naoki Takegawa.;Takeshi Kajiwara.;Hideo Baba.;Masaki Ueno.;Hiroya Takeuchi.;Kenichi Nakamura.;Yuko Kitagawa.; .
来源: Lancet. 2024年404卷10447期55-66页
Neoadjuvant therapy is the standard treatment for patients with locally advanced oesophageal squamous cell carcinoma (OSCC). However, the prognosis remains poor and more intensive neoadjuvant treatment might be needed to improve patient outcomes. We therefore aimed to compare the efficacy and safety of neoadjuvant doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus radiotherapy in patients with previously untreated locally advanced OSCC.
1359. Stereotactic radiotherapy for neovascular age-related macular degeneration (STAR): a pivotal, randomised, double-masked, sham-controlled device trial.
作者: Timothy L Jackson.;Riti Desai.;Hatem A Wafa.;Yanzhong Wang.;Janet Peacock.;Tunde Peto.;Usha Chakravarthy.;Helen Dakin.;Sarah Wordsworth.;Cornelius Lewis.;Patricia Clinch.;Lisa Ramazzotto.;James E Neffendorf.;Chan Ning Lee.;Joe M O'Sullivan.;Barnaby C Reeves.; .
来源: Lancet. 2024年404卷10447期44-54页
Neovascular age-related macular degeneration (nAMD) is a leading cause of blindness. The first-line therapy is anti-vascular endothelial growth factor (anti-VEGF) agents delivered by intravitreal injection. Ionising radiation mitigates key pathogenic processes underlying nAMD, and therefore has therapeutic potential. STAR aimed to assess whether stereotactic radiotherapy (SRT) reduces the number of anti-VEGF injections required, without sacrificing visual acuity.
1360. Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.
作者: Peter Kelly.;Robin Lemmens.;Christian Weimar.;Cathal Walsh.;Francisco Purroy.;Mark Barber.;Ronan Collins.;Simon Cronin.;Anna Czlonkowska.;Philippe Desfontaines.;Adinda De Pauw.;Nicholas Richard Evans.;Urs Fischer.;Catarina Fonseca.;John Forbes.;Michael D Hill.;Dalius Jatuzis.;Janika Kõrv.;Peter Kraft.;Christina Kruuse.;Catherine Lynch.;Dominick McCabe.;Robert Mikulik.;Sean Murphy.;Paul Nederkoorn.;Martin O'Donnell.;Peter Sandercock.;Bernadette Schroeder.;Gek Shim.;Katrina Tobin.;David J Williams.;Christopher Price.
来源: Lancet. 2024年404卷10448期125-133页
Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke.
|